You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 君實生物港A齊升 與Coherus擴大腫瘤免疫領域合作
格隆匯1月12日丨君實生物(1877.HK)漲超6%報47.35港元,A股漲超5%報64.98元。君實生物AH股近期走出大漲大跌行情,漲幅波動較為明顯。公司與Coherus公司共同宣佈,雙方將擴大於2021年達成的腫瘤免疫領域合作。Coherus將向君實生物支付3500萬美元首付款,最高達2.55億美元的開發、申報和銷售里程碑付款,以及產品銷售淨額18%的銷售分成。另外,公司VV116正分別於國內以及烏茲別克斯坦積極推進臨牀試驗,並已在烏茲別克斯坦獲得緊急使用授權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account